Scientific Clinical Institutes Maugeri SpA
This study will test the Safety and activity of pembrolizumab plus chemotherapy as neoadjuvant treatment in locally advanced sinonasal undifferentiated carcinoma (SNUC). Activity of neoadjuvant chemotherapy in locally advanced SNUC has been already demonstrated; the primary hypothesis is that the addition of pembrolizumab as neoadjuvant and adjuvant agent might confirm the results obtained with a combined treatment strategy including chemotherapy, decreasing the burden of treatment-related side effects.
Sinonasal Undifferentiated Carcinoma
Pembrolizumab
Cisplatin
Docetaxel
Carboplatin
PHASE2
Study Type : | INTERVENTIONAL |
Estimated Enrollment : | 28 participants |
Masking : | NONE |
Primary Purpose : | TREATMENT |
Official Title : | Neoadjuvant Pembrolizumab Plus Chemotherapy in Locally Advanced Sinonasal Carcinoma |
Actual Study Start Date : | 2024-10 |
Estimated Primary Completion Date : | 2026-11 |
Estimated Study Completion Date : | 2026-11 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Maugeri Scientific Clinical Institutes
Pavia, Lombardy, Italy, 27100